City Holding (NASDAQ:CHCO) Beats Q2 CY2026 Sales Expectations

City Holding (NASDAQ: CHCO) reported Q2 CY2026 sales of $81.74 million, up 4.1% year over year, beating market revenue expectations by 1.3%. Non-GAAP profit was $2.35 per share, 5.6% above analysts’ consensus. The article also cites tangible book value per share rising from $35.75 to $46.40 over two years.

Original reporting
Published Jul 22, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
City Holding (NASDAQ:CHCO) Beats Q2 CY2026 Sales Expectations — source image
Decision brief

The 30-second read

$CHCOBullishMed
01

Why it matters

The key tradable takeaway is the reported Q2 CY2026 beat versus analysts’ revenue and non-GAAP EPS expectations, plus TBVPS beating expectations, which can influence near-term valuation and positioning for CHCO.

02

Market read

CHCO’s earnings print provides a concrete beat on revenue and EPS, with TBVPS also outperforming, but the stock was flat immediately after results, suggesting limited immediate repricing.

03

What to watch

The text emphasizes net interest income as the dominant revenue source but does not provide rate sensitivity, deposit costs, or credit quality details that typically drive follow-through after bank earnings.

Relevance 6/10Novelty 6/10Timing: after-hours/after Q2 CY2026 results release (published 2026-07-22 21:15 UTC)

Background

City Holding is a regional financial holding company operating through City National Bank, with results framed around revenue growth, net interest income, and tangible book value per share (TBVPS).

Company-level read

Ticker impact

$CHCOBullishMedium confidence
Context

City Holding reported Q2 CY2026 sales of $81.74M, up 4.1% YoY, and non-GAAP EPS of $2.35, beating consensus estimates.

Expected impact

Likely supports continued upside bias versus pre-report expectations, though the stock reportedly stayed flat at $139.09 immediately after results.

Evidence & confidence

The article provides specific reported figures versus consensus (revenue and EPS) and notes TBVPS beat, but also states the stock was flat right after the release, limiting immediate follow-through expectations.

Market effects

A regional bank beat on revenue and TBVPS can modestly support sentiment toward similar balance-sheet and net-interest-income focused peers.

Limited to regional banking sentiment, given City Holding’s footprint across West Virginia, Kentucky, Virginia, and Ohio.

Low, as the disclosure is company-specific and not tied to global macro or cross-border events.

Counterpoint

The article flags only modest revenue growth (4.1% YoY) and calls TBVPS growth over the next 12 months “paltry,” which could cap upside despite the beat.

Key entities

  • City Holding

    Reported Q2 CY2026 sales of $81.74M (+4.1% YoY) and non-GAAP EPS of $2.35 (+5.6% above consensus), with TBVPS beating expectations.

Related articles

$CHCOMed

CITY HOLDING CO (CHCO): Results of Operations and Financial Condition

CITY HOLDING CO (CHCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chco06-30x2026exhibit991.htm EX-99.1 Document NEWS RELEASE For Immediate Release July 22, 2026 For Further Information Contact: David L. Bumgarner, Senior Executive Vice President and Chief Financial Officer (304) 769-1169 City Holding Company Announces Quarterly Result

$CHCOMedAI 8/10

City Holding Company (NASDAQ:CHCO) Plans $0.87 Quarterly Dividend

City Holding Company (NASDAQ:CHCO) declared a quarterly dividend of $0.87 per share, payable July 31 to shareholders of record July 15. The dividend implies a 2.8% yield and an annualized $3.48. The company reported Q1 EPS of $2.20 on $79.25M revenue and said its board authorized a stock repurchase of up to 1,000,000 shares.

$NVOMedAI 8/10

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk reported Q2 adjusted sales of DKK 78.5 billion, with obesity care sales up 16% and GLP-1 diabetes up 2%. Adjusted gross margin fell to 78.2% from 82.7% due to lower prices, about DKK 3 billion one-time manufacturing-cost items, and FX. The company raised 2026 outlook to 0% to -6% adjusted sales and operating profit growth. ZEUS ziltivekimab trial missed its primary endpoint (HR 0.99).

$NYTMed

New York Times Q2 Earnings Call Highlights

The New York Times Company (NYSE:NYT) reported Q2 results on its earnings call. Digital-only subscribers rose 13.3% YoY and digital-only ARPU increased 3.1%. First-half free cash flow was about $266M and the company returned about $160M to shareholders. It guided Q3 digital-only subscription revenue up 12% to 15% and digital ad revenue up mid- to high-teens.

$OCMed

Owens Corning Q2 Earnings Call Highlights

Owens Corning (NYSE:OC) said Iran-related net cost impact is expected to be about $40 million in Q3, with roofing the most affected segment. The company reported Q2 liquidity of $1.8 billion and plans to repay $400 million of senior notes in Q3. Full-year capex is about $800 million. Roofing Q2 sales were ~$1.3 billion; insulation revenue rose 4% to $971 million.

$OFRMMedAI 8/10

Once Upon A Farm Q2 Earnings Call Highlights

Once Upon a Farm (NYSE:OFRM) reported Q2 growth, with baby sales up 73% to $41.5M and kid sales up 22% to $43.9M, alongside distribution point expansion. Gross margin fell to 35.9% (down 485 bps). SG&A rose to $36.3M. Net loss was $5M. The company cut FY gross margin outlook to ~40% and expects Q3 similar margins.